Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on clinical data releases, financial results, and material corporate agreements for this commercial-stage biopharmaceutical company focused on targeted cancer therapies.
Day One uses Form 8-K to report material events such as updated three-year data from the pivotal FIREFLY-1 trial of OJEMDA™ (tovorafenib) in pediatric low-grade glioma, financial results for specific quarters, and changes to corporate presentations. For example, an 8-K dated November 24, 2025 describes FIREFLY-1 efficacy and safety outcomes, while other 8-Ks attach press releases and slide decks summarizing OJEMDA net product revenue, license revenue, operating expenses, and cash balances.
Filings also document transactional and corporate actions. An 8-K filed in November 2025 outlines the Agreement and Plan of Merger through which Day One agreed to acquire Mersana Therapeutics via a tender offer and subsequent merger, including the structure of cash consideration and contingent value rights. Another 8-K describes an option repricing approved by the board of directors, providing detail on how stock options for certain directors and employees are adjusted and conditioned on continued service.
Through these SEC documents, readers can examine how Day One reports clinical trial outcomes, such as response rates and treatment-free intervals from FIREFLY-1, as well as how it communicates financial performance and corporate governance decisions. Stock Titan’s interface surfaces these filings alongside AI-powered summaries that highlight key points, helping users quickly understand the context of each report while preserving access to the full underlying documents.
In addition to 8-Ks, investors may use this page as a starting point to locate Day One’s annual and quarterly reports, which provide broader overviews of its oncology pipeline, including OJEMDA, DAY301, and Emi-Le, and its status as a Nasdaq Global Select Market registrant under the symbol DAWN.
Day One Biopharmaceuticals amends its Schedule 14D-9 to revise Centerview Partners’ valuation analyses and to add disclosures about related shareholder litigation. The filing restates selected public-company and precedent-transaction multiples, updates a DCF and management projections, and discloses two complaints and additional demand letters concerning the proposed merger.
The amendment compares Centerview’s implied equity ranges of $11.80 to $20.00 and $17.25 to $25.40 per share to the $21.50 per-share offer. It also cites Day One’s projected $645M 2029 risk-adjusted revenue, estimated net cash of $314M, and a fully-diluted share base of approximately 103.3 million shares (with ~15.3 million options, 3.7 million RSUs and 0.8 million pre-funded warrants).
AI Day1 LLC and its affiliates updated their ownership filing on Day One Biopharmaceuticals after tendering their entire stake into a cash buyout offer. On April 9, 2026, AI Day1 tendered 12,929,322 shares of Common Stock to Servier Detroit Inc.’s tender offer at $21.50 per share in cash.
The reporting group’s stake represented 12.52% of Day One’s Common Stock, based on 103,297,691 shares outstanding as of February 19, 2026. AI Day1 also directly holds warrants to purchase 827,586 additional shares, which may be deemed beneficially owned indirectly by Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik, although each of them disclaims beneficial ownership.
Servier S.A.S. and its subsidiaries amended the Schedule TO to report that the FTC granted early termination of the HSR waiting period, effective April 7, 2026 at 1:37 p.m. Eastern Time. This satisfies the HSR condition listed in Section 15 of the offer.
The tender offer for all outstanding shares of Day One Biopharmaceuticals, Inc. remains subject to the Offer's other conditions set forth in Section 15. The amendment supplements Item 11 (Certain Legal Matters; Regulatory Approvals) and otherwise leaves the Schedule TO unchanged.
Day One Biopharmaceuticals amended its Schedule 14D-9 to report that the premerger waiting period under the Hart‑Scott‑Rodino Act was terminated early by the FTC on April 7, 2026 at 1:37 p.m. Eastern Time. The company confirms the HSR condition to the cash tender offer at $21.50 per share has been satisfied; the Offer remains subject to the other conditions set forth in the Offer to Purchase.
Day One Biopharmaceuticals Inc. Schedule 13G/A reports that FMR LLC (with Abigail P. Johnson listed) beneficially owns 23,639.69 shares of common stock, representing 0.0% of the class as reported. The filing is an amendment and is signed under powers of attorney dated in 2023.
Day One Biopharmaceuticals Inc received an amended Schedule 13G/A from The Vanguard Group reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class as disclosed in the amendment. The filing explains an internal realignment completed on January 12, 2026 that led certain Vanguard subsidiaries and business divisions to report holdings separately, and the form is signed by Ashley Grim, Head of Global Fund Administration.
Servier Parties amend Schedule TO for Day One Biopharmaceuticals. Servier S.A.S., Servier Pharmaceuticals LLC and Purchaser Servier Detroit Inc. filed Amendment No. 1 to their Schedule TO, supplementing the pending tender offer for all issued and outstanding common shares of Day One Biopharmaceuticals by adding an Integration Presentation as an exhibit.
Day One Biopharmaceuticals recommends that stockholders accept a cash tender offer by Servier at $21.50 per share. The Offer, commenced March 26, 2026 and scheduled to expire April 22, 2026, is subject to conditions including at least a majority of Shares tendered, HSR clearance and other customary closing conditions. Day One had 103,317,336 Shares outstanding as of March 20, 2026; pre-funded warrants to purchase 827,586 shares are outstanding. Following the Offer and subject to conditions, Purchaser will merge into Day One under Section 251(h) of the DGCL and Day One will become a wholly owned subsidiary of Parent. Company executives and directors beneficially owned 2,418,391 Shares as of March 20, 2026 and, if tendered and accepted, would receive approximately $51,995,407 in the aggregate before withholding.
Day One Biopharmaceuticals, Inc. announced a cash tender offer by Servier Detroit Inc. to acquire all issued and outstanding common shares at $21.50 per share. The offer is made pursuant to the Offer to Purchase dated March 26, 2026 and is payable in cash, net to stockholders, without interest and less any applicable tax withholding. The Schedule TO incorporates the Offer to Purchase and related Letter of Transmittal and lists the Agreement and Plan of Merger dated March 6, 2026 as an exhibit. The filing includes customary transaction exhibits and communications related to the tender offer.